Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors

NCT02826928 is registered in ClinicalTrials.gov with CHU de Reims as lead sponsor.

NCT NCT02826928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02826928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors
Lead sponsor
CHU de Reims
Phase
Not applicable
Overall status
Completed
Start date
October 26, 2016
Completion date
June 3, 2022
Enrollment
116 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small-intestine neuroendocrine tumors (carcinoid tumors)